Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding
Sponsor: BioMarin Pharmaceutical
Summary
This is a Phase 4 observational study designed to assess the impact of Palynziq ® (pegvaliase) treatment in pregnant women with PKU and on their offspring who were exposed to pegvaliase at any time during pregnancy and breastfeeding.
Key Details
Gender
FEMALE
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2022-11-22
Completion Date
2032-10-04
Last Updated
2026-03-24
Healthy Volunteers
Not specified
Conditions
Interventions
Pegvaliase
Pregnant women exposed to pegvaliase within 2 weeks prior to LMP.
Locations (4)
Syneos Health
Wilmington, North Carolina, United States
Metabolics and Genetics in Calgary (MAGIC)
Calgary, Canada
Universitaetsklinikum Hamburg Eppendorf
Hamburg, Germany
Ospedale San Paolo
Milan, Italy